vs
Apellis Pharmaceuticals, Inc.（APLS）与康耐视（CGNX）财务数据对比。点击上方公司名可切换其他公司
康耐视的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$268.4M vs $199.9M），康耐视净利率更高（19.3% vs -29.5%，领先48.7%），康耐视同比增速更快（24.3% vs -5.9%），康耐视自由现金流更多（$42.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
康耐视（Cognex Corporation）是总部位于美国马萨诸塞州内蒂克的机器视觉系统、软件及传感器制造商，业务覆盖全球20余个国家和地区，为各工业领域客户提供高性能的视觉相关产品及解决方案。
APLS vs CGNX — 直观对比
营收规模更大
CGNX
是对方的1.3倍
$199.9M
营收增速更快
CGNX
高出30.2%
-5.9%
净利率更高
CGNX
高出48.7%
-29.5%
自由现金流更多
CGNX
多$56.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $268.4M |
| 净利润 | $-59.0M | $51.7M |
| 毛利率 | — | 71.1% |
| 营业利润率 | -25.6% | 22.4% |
| 净利率 | -29.5% | 19.3% |
| 营收同比 | -5.9% | 24.3% |
| 净利润同比 | -62.2% | 119.1% |
| 每股收益（稀释后） | $-0.40 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCGNX
| Q1 26 | — | $268.4M | ||
| Q4 25 | $199.9M | $252.3M | ||
| Q3 25 | $458.6M | $276.9M | ||
| Q2 25 | $178.5M | $249.1M | ||
| Q1 25 | $166.8M | $216.0M | ||
| Q4 24 | $212.5M | $229.7M | ||
| Q3 24 | $196.8M | $234.7M | ||
| Q2 24 | $199.7M | $239.3M |
净利润APLSCGNX
| Q1 26 | — | $51.7M | ||
| Q4 25 | $-59.0M | $32.7M | ||
| Q3 25 | $215.7M | $17.7M | ||
| Q2 25 | $-42.2M | $40.5M | ||
| Q1 25 | $-92.2M | $23.6M | ||
| Q4 24 | $-36.4M | $28.3M | ||
| Q3 24 | $-57.4M | $29.6M | ||
| Q2 24 | $-37.7M | $36.2M |
毛利率APLSCGNX
| Q1 26 | — | 71.1% | ||
| Q4 25 | — | 65.7% | ||
| Q3 25 | — | 67.6% | ||
| Q2 25 | — | 67.4% | ||
| Q1 25 | — | 66.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 67.9% | ||
| Q2 24 | — | 69.6% |
营业利润率APLSCGNX
| Q1 26 | — | 22.4% | ||
| Q4 25 | -25.6% | 14.0% | ||
| Q3 25 | 48.7% | 20.9% | ||
| Q2 25 | -18.6% | 17.4% | ||
| Q1 25 | -50.0% | 12.1% | ||
| Q4 24 | -12.3% | 13.4% | ||
| Q3 24 | -24.0% | 13.4% | ||
| Q2 24 | -14.7% | 16.1% |
净利率APLSCGNX
| Q1 26 | — | 19.3% | ||
| Q4 25 | -29.5% | 12.9% | ||
| Q3 25 | 47.0% | 6.4% | ||
| Q2 25 | -23.6% | 16.3% | ||
| Q1 25 | -55.3% | 10.9% | ||
| Q4 24 | -17.1% | 12.3% | ||
| Q3 24 | -29.2% | 12.6% | ||
| Q2 24 | -18.9% | 15.1% |
每股收益（稀释后）APLSCGNX
| Q1 26 | — | $0.31 | ||
| Q4 25 | $-0.40 | $0.20 | ||
| Q3 25 | $1.67 | $0.10 | ||
| Q2 25 | $-0.33 | $0.24 | ||
| Q1 25 | $-0.74 | $0.14 | ||
| Q4 24 | $-0.30 | $0.17 | ||
| Q3 24 | $-0.46 | $0.17 | ||
| Q2 24 | $-0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $237.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.5B |
| 总资产 | $1.1B | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCGNX
| Q1 26 | — | $237.3M | ||
| Q4 25 | $466.2M | $262.9M | ||
| Q3 25 | $479.2M | $245.9M | ||
| Q2 25 | $370.0M | $179.3M | ||
| Q1 25 | $358.4M | $143.7M | ||
| Q4 24 | $411.3M | $186.1M | ||
| Q3 24 | $396.9M | $197.1M | ||
| Q2 24 | $360.1M | $176.6M |
股东权益APLSCGNX
| Q1 26 | — | $1.5B | ||
| Q4 25 | $370.1M | $1.5B | ||
| Q3 25 | $401.2M | $1.5B | ||
| Q2 25 | $156.3M | $1.5B | ||
| Q1 25 | $164.2M | $1.4B | ||
| Q4 24 | $228.5M | $1.5B | ||
| Q3 24 | $237.1M | $1.6B | ||
| Q2 24 | $264.3M | $1.5B |
总资产APLSCGNX
| Q1 26 | — | $2.0B | ||
| Q4 25 | $1.1B | $2.0B | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $2.0B | ||
| Q3 24 | $901.9M | $2.1B | ||
| Q2 24 | $904.5M | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $42.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 15.8% |
| 资本支出强度资本支出/营收 | 0.1% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $241.1M |
8季度趋势，按日历期对齐
经营现金流APLSCGNX
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $74.9M | ||
| Q3 25 | $108.5M | $87.5M | ||
| Q2 25 | $4.4M | $42.6M | ||
| Q1 25 | $-53.4M | $40.5M | ||
| Q4 24 | $19.4M | $51.4M | ||
| Q3 24 | $34.1M | $56.3M | ||
| Q2 24 | $-8.3M | $27.8M |
自由现金流APLSCGNX
| Q1 26 | — | $42.3M | ||
| Q4 25 | $-14.3M | $72.3M | ||
| Q3 25 | $108.3M | $86.0M | ||
| Q2 25 | $4.4M | $40.4M | ||
| Q1 25 | $-53.4M | $38.0M | ||
| Q4 24 | $19.3M | $49.3M | ||
| Q3 24 | — | $51.9M | ||
| Q2 24 | $-8.4M | $23.3M |
自由现金流率APLSCGNX
| Q1 26 | — | 15.8% | ||
| Q4 25 | -7.1% | 28.7% | ||
| Q3 25 | 23.6% | 31.1% | ||
| Q2 25 | 2.5% | 16.2% | ||
| Q1 25 | -32.0% | 17.6% | ||
| Q4 24 | 9.1% | 21.5% | ||
| Q3 24 | — | 22.1% | ||
| Q2 24 | -4.2% | 9.7% |
资本支出强度APLSCGNX
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 1.9% | ||
| Q2 24 | 0.0% | 1.9% |
现金转化率APLSCGNX
| Q1 26 | — | — | ||
| Q4 25 | — | 2.29× | ||
| Q3 25 | 0.50× | 4.95× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 1.72× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 0.77× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CGNX
暂无分部数据
